Combined cabazitaxel and carboplatin treatment of metastatic castration resistant prostate cancer patients, with innate or acquired resistance to cabazitaxel monotherapy

•Innate or acquired resistance to cabazitaxel in mCRPC patients is a common event•Addition of carboplatin in these cases, results in a secondary response•Secondary PSA responses are found in approximately a quarter of patients•In our study a secondary response was not related to genetic mutations•In our study a secondary response was not related to clinical features